Subcutaneous Rituximab in Follicular Lymphoma, Chronic Lymphocytic Leukemia, and Diffuse Large B-Cell Lymphoma

Rituximab and hyaluronidase human is a new subcutaneous formulation of rituximab that was recently approved by the US Food and Drug Administration for the treatment of adults with follicular lymphoma, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia. With data to support noninferior p...

Descripción completa

Detalles Bibliográficos
Autor principal: Yelvington, Bradley J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Harborside Press 2018
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6505540/
https://www.ncbi.nlm.nih.gov/pubmed/31086689
_version_ 1783416777532768256
author Yelvington, Bradley J.
author_facet Yelvington, Bradley J.
author_sort Yelvington, Bradley J.
collection PubMed
description Rituximab and hyaluronidase human is a new subcutaneous formulation of rituximab that was recently approved by the US Food and Drug Administration for the treatment of adults with follicular lymphoma, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia. With data to support noninferior pharmacokinetics, similar outcomes, and comparable adverse events, rituximab and hyaluronidase human may offer a suitable alternative to intravenous rituximab that could improve convenience for patients and better utilize health-care resources.
format Online
Article
Text
id pubmed-6505540
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Harborside Press
record_format MEDLINE/PubMed
spelling pubmed-65055402019-05-13 Subcutaneous Rituximab in Follicular Lymphoma, Chronic Lymphocytic Leukemia, and Diffuse Large B-Cell Lymphoma Yelvington, Bradley J. J Adv Pract Oncol Review Article Rituximab and hyaluronidase human is a new subcutaneous formulation of rituximab that was recently approved by the US Food and Drug Administration for the treatment of adults with follicular lymphoma, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia. With data to support noninferior pharmacokinetics, similar outcomes, and comparable adverse events, rituximab and hyaluronidase human may offer a suitable alternative to intravenous rituximab that could improve convenience for patients and better utilize health-care resources. Harborside Press 2018 2018-07-01 /pmc/articles/PMC6505540/ /pubmed/31086689 Text en Copyright © 2018, Harborside Press http://creativecommons.org/licenses/by-nc/3.0/ This article is distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Yelvington, Bradley J.
Subcutaneous Rituximab in Follicular Lymphoma, Chronic Lymphocytic Leukemia, and Diffuse Large B-Cell Lymphoma
title Subcutaneous Rituximab in Follicular Lymphoma, Chronic Lymphocytic Leukemia, and Diffuse Large B-Cell Lymphoma
title_full Subcutaneous Rituximab in Follicular Lymphoma, Chronic Lymphocytic Leukemia, and Diffuse Large B-Cell Lymphoma
title_fullStr Subcutaneous Rituximab in Follicular Lymphoma, Chronic Lymphocytic Leukemia, and Diffuse Large B-Cell Lymphoma
title_full_unstemmed Subcutaneous Rituximab in Follicular Lymphoma, Chronic Lymphocytic Leukemia, and Diffuse Large B-Cell Lymphoma
title_short Subcutaneous Rituximab in Follicular Lymphoma, Chronic Lymphocytic Leukemia, and Diffuse Large B-Cell Lymphoma
title_sort subcutaneous rituximab in follicular lymphoma, chronic lymphocytic leukemia, and diffuse large b-cell lymphoma
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6505540/
https://www.ncbi.nlm.nih.gov/pubmed/31086689
work_keys_str_mv AT yelvingtonbradleyj subcutaneousrituximabinfollicularlymphomachroniclymphocyticleukemiaanddiffuselargebcelllymphoma

Ejemplares similares